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Abstract
Background: Abiraterone acetate received licencing for use in only “high-risk” meta-
static hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings.
However, a “risk”-related effect was not seen in the STAMPEDE trial. There remains
uncertainty as to whether men with LATITUDE “low-risk” M1 disease benefit from
androgen deprivation therapy (ADT) combined with abiraterone acetate and predniso-
lone (AAP).
Objective: Evaluation of heterogeneity of effect between LATITUDE high- and low-risk
M1 prostate cancer patients receiving ADT + AAP in the STAMPEDE trial.
Design, setting, and participants: A post hoc subgroup analysis of the 2017 STAMPEDE
“abiraterone comparison”. Staging scans for M1 patients contemporaneously random-
ised to ADT or ADT + AAP within the STAMPEDE trial were evaluated centrally and blind
to treatment assignment. Stratiﬁcation was by risk according to the criteria set out in the
LATITUDE trial. Exploratory subgroup stratiﬁcation incorporated the CHAARTED criteria.
Outcome measurements and statistical analysis: The primary outcome measure was
overall survival (OS) and the secondary outcome measure was failure-free survival (FFS).
Further exploratory analysis evaluated clinical skeletal-related events, progression-free
survival (PFS), and prostate cancer-speciﬁc death. Standard Cox-regression and Kaplan-
Meier survival estimates were employed for analysis.
1 David Matheson and Robin Millman are patient representatives.
2 For a list of STAMPEDE Investigators, see Supplementary data.
* Corresponding author at: Department of Surgery, The Christie NHS Foundation Trust, Wilmslow
Road, Manchester M20 4BX, UK. Tel. +44 (0) 1617897373; Fax: +44 7921149832.
E-mail address: noel.clarke@christie.nhs.uk (N.W. Clarke).
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1. Introduction
Two randomised controlled trials have reported survival gains
for men with metastatic hormone-naïve prostate cancer
(mHNPC) treated with androgen deprivation therapy (ADT)
plus abiraterone acetate and prednisolone/prednisone (AAP)
compared with ADT alone [1,2]. These results have established
ADT + AAP as an alternative standard of care to ADT + doc-
etaxel in the treatment of men with mHNPC. However, there
are important differences in the design of the two trials
regarding inclusion of patients based on their disease burden:
LATITUDE recruited only newly diagnosed metastatic (M1)
patients with “high-risk” disease starting long-term ADT for
the first time, whereas STAMPEDE recruited nonmetastatic
(M0) and M1 patients without risk stratification. The
LATITUDE trial defined high-risk disease according to a
combination of poor prognostic radiological and/or patholog-
ical features. In 2018, the European Medicines Agency and the
Food and Drug Administration licensed AAP for the treatment
of M1 patients with “high-risk” disease only [3,4]. Uncertainty
now exists regarding the treatment benefit for patients with
“low-risk” M1 disease. To address this, patients in the
“abiraterone comparison” of STAMPEDE underwent image-
based post hoc subset analysis, stratified retrospectively by
baseline staging risk to assess whether ADT + AAP is effective
in low- as well as high-risk M1 disease.
2. Patients and methods
2.1. Trial design
STAMPEDE uses a multiarm multistage platform [5] design to
test multiple treatment approaches against control [6–9]. All
patients relevant to this comparison were randomised to
ADT + AAP (trial arm G) or ADT alone (trial arm A). Patients
underwent baseline imaging prior to randomisation, including
computed tomography (CT) or magnetic resonance imaging
(MRI) of the pelvis/abdomen, and a technetium-99 bone scan
before 1:1 randomisation to ADT + AAP or ADT alone.
2.2. Cohort selection and imaging review
Patients from the “abiraterone comparison” group were
excluded from this analysis only if they had incomplete
information precluding classification into low or high
risk. Baseline bone scintigraphic images from patients
with bone metastases were reviewed centrally for risk
stratification by a urologist (A.H.). Quality control was
performed by independent random sample reporting by
an independent consultant radiologist (H.D.) blinded to
both treatment assignment and the findings of the first
investigator. A random sample of 85 patients underwent
such a review. The primary and secondary scan readers
were blinded to treatment allocation and outcome during
all scan assessments. Providing there was sufficient
concordance (>90%), the primary reader’s assessments
would be used.
The radiological criteria for classification into low/high
risk were based upon the LATITUDE trial because of its
current influence in treatment registration in mHNPC
[1,2]. This defined high-risk disease as having any two of
the following: (1) three or more bone metastases on bone
scan, (2) Gleason sum 8, and (3) any visceral metastases.
The analysis was also applied to the same population
stratified by volume criteria used in the CHAARTED trial
[10], defining high-volume disease as: (1) four or more bone
metastases on bone scan, including one or more outside the
vertebral bodies or pelvis, and/or (2) visceral metastases
[10]. The number and location of bone metastases were
recorded, and then combined with documented diagnostic
biopsy Gleason score and the presence of visceral metasta-
ses on CT/MRI, permitting stratification by the LATITUDE
and CHAARTED criteria.
2.3. Statistical analyses
The primary outcome measure was overall survival (OS) and
the secondary outcome was failure-free survival (FFS): this
was defined as radiological, clinical, or prostate-specific
antigen progression, or death from prostate cancer as per
the predefined STAMPEDE criteria [2]. Other outcome
measures evaluated were clinical skeletal-related events
(SREs), progression-free survival (PFS), and prostate cancer–
specific death (PCSD), defined previously [11]. Data from the
published “abiraterone comparison”, frozen from the trial
database on 10 February 2017, were used for survival
analyses [2]. The data lock date for the retrospective scan
data was 1 August 2018.
Results and limitations: A total of 901 M1 STAMPEDE patients were evaluated after
exclusions. Of the patients, 428 (48%) were identiﬁed as having a low risk and 473 (52%)
a high risk. Patients receiving ADT + AAP had signiﬁcantly improved OS (low-risk hazard
ratio [HR]: 0.66, 95% conﬁdence interval or CI [0.44–0.98]) and FFS (low-risk HR: 0.24,
95% CI [0.17–0.33]) compared with ADT alone. Heterogeneity of effect was not seen
between low- and high-risk groups for OS or FFS. For OS beneﬁt in low risk, the number
needed to treat was four times greater than that for high risk. However, this was not
observed for the other measured endpoints.
Conclusions: Men with mHNPC gain treatment beneﬁt from ADT + AAP irrespective of
risk stratiﬁcation for “risk” or “volume”.
Patient summary: Coadministration of abiraterone acetate and prednisolone with
androgen deprivation therapy (ADT) is associated with prolonged overall survival
and disease control, compared with ADT alone, in all men with metastatic disease
starting hormone therapy for the ﬁrst time.
© 2019 Published by Elsevier B.V. on behalf of European Association of Urology.
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Prior to analysis, we prespecified the hypothesis that
there would be no difference in the treatment effect from
adding AAP across the subgroups.
Kaplan-Meier methods were used to plot survival curves
and Cox proportional hazard models to estimate relative
treatment effects. Cox models were adjusted for randomisa-
tion stratification factors (except for randomising centre,
presence or absence of metastases, type of ADT, and planned
use of prostate radiotherapy) and stratified according to time
periods defined by corecruiting trial arms. Proportional-
hazard assumptions were checked. A hazard ratio (HR) of <1
represents evidence for ADT + AAP, and an HR of >1 represents
benefit of ADT alone. Confidence intervals (CIs) are reported at
95% levels. Heterogeneity of treatment effects among M1 risk
subgroups were evaluated using interaction terms in the
adjusted Cox regression models. Time-to-event analyses used
time from randomisation to the outcome of interest, with
those not reporting the event censored at the time of last
contact. Median follow-up was determined from reverse
censoring from death. All analyses were performed using Stata
v15 (StataCorp LP, College Station, TX, USA).
3. Results
3.1. Study cohort
Between 15 November 2011 and 17 January 2014,
990 mHNPC M1 patients were randomised to receive
ADT alone or with AAP. Patients with incomplete informa-
tion precluding radiological risk-based classification were
excluded as follows: absent Gleason score (n = 34), unobtain-
able bone scintigraphy (n = 41), and bone metastases diag-
nosed using nonconventional imaging (n = 14). A total of
901 mHNPC patients underwent stratification using the
LATITUDE risk criteria (Fig. 1) and, thereafter, the CHAARTED
volume criteria. Baseline characteristics by LATITUDE- and
CHAARTED-defined risk/volume subgroups were balanced
between the two treatment arms (Table 1). In all, 428 (48%)
patients were classified as having a low risk by the LATITUDE
criteria and 402 (45%) using the CHAARTED criteria. High-risk
disease using the LATITUDE and CHAARTED criteria was seen
in 473 (52%) and 499 (55%) patients, respectively. Median
follow-up of the cohort was 42 mo.
3.2. Quality control
In total, 759 patients had bone metastases. A random
sample of 85 (11%) patients from this population was
included in the quality control process. Concordance
between the primary and independent reviewer for the
volume subgroup classification was 92% (78/85).
3.3. Overall survival
Of 901 patients, 330 (195 ADT; 135 ADT + AAP) had died.
When stratified according to the LATITUDE criteria for low
Fig. 1 – Consort diagram showing the UK M1 study cohort selection for metastatic volume stratification using CHAARTED and LATITUDE definitions. A
2 T 2 shows matched and unmatched proportions of high- and low-volume/risk patients using the LATITUDE and CHAARTED definitions. Percentages
in brackets are based on the whole study population (n = 901). AAP = abiraterone acetate and prednisolone; SOC = standard of care.
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Table 1 – Baseline patient characteristics of 901 M1 patients included and defined for LATITUDE risk and CHAARTED volume criteria.
STAMPEDE abiraterone
volume analysis (n= 901)
LATITUDE criteria CHAARTED criteria
Low risk (n= 428) High risk (n= 473) Low risk (n=402) High risk (n= 499)
ADT
(n =220)
ADT+AAP
(n =208)
p value ADT
(n =232)
ADT+AAP
(n=241)
p value ADT
(n= 196)
ADT+AAP
(n =206)
p value ADT
(n= 256)
ADT+AAP
(n= 243)
p value
Age at randomisation
Median 66 66 0.37 67 67 0.75 67 66 0.14 67 68 0.36
IQR 62–72 62–71 63–72 63–71 63–72 61–71 62–72 64–72
PSA prior to ADT
Median 51 70 0.14 174 126 0.28 45 53 0.19 177 174 0.94
IQR 19–148 24–198 40–735 36–458 16–121 20–132 45–786 55–657
WHO performance status
0 174 158 0.44 163 177 0.44 155 164 0.90 182 171 0.86
1–2 46 50 69 64 41 42 74 72
Gleason sum
7 107 102 0.93 3 2 0.62 54 61 0.65 56 43 0.24
8–10 113 106 229 239 142 145 200 200
Primary tumour stage
T2 26 23 0.50 23 21 0.32 19 22 0.97 30 22 0.22
T3 133 125 116 141 120 122 129 144
T4 54 47 68 59 46 49 76 57
TX 7 13 25 20 11 13 21 20
Regional node status
N0 80 66 0.49 78 84 0.36 61 67 0.92 97 83 0.37
N+ 125 130 137 131 122 127 140 134
NX 15 12 17 26 13 12 19 26
Eligibility
M+, new 202 190 0.86 229 238 0.96 182 191 0.96 249 237 0.85
Previously treated 18 18 3 3 14 15 7 6
Metastatic site
Node 47 55 0.55 – – 0.77 47 55 0.61 – – 0.89
Bone 140 127 154 169 116 123 178 173
Visceral 1 1 1 – – – 2 1
Bone +node 32 24 60 52 33 28 59 48
Bone + visceral – – 9 12 – – 9 12
Visceral +node – – 1 1 – – 1 1
Bone +node +visceral – 1 7 7 – – 7 8
AAP= abiraterone acetate and prednisolone; ADT= androgen deprivation therapy; IQR= interquartile range; PSA=prostate-speciﬁc antigen.
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risk, the ADT + AAP combination therapy demonstrated a
survival advantage (HR: 0.66, 95% CI [0.44–0.98]): absolute
3-yr survival was 83% with ADT + AAP and 78% with ADT
alone (Fig. 2A). Improvement was also seen in the high-risk
disease subgroup (HR: 0.54, 95% CI [0.41–0.70]): absolute 3-
yr survival was 65% with ADT + AAP and 45% with ADT
(Fig. 2B). The heterogeneity of treatment effect between
high- and low-risk groups was not statistically significant
(p-interaction = 0.39, Fig. 3), although for OS, the number of
patients needed treatment (20 vs five) to prevent one death
after 3 yr in the low-risk group was four times more than
that in the high-risk group.
3.4. Failure-free survival
This population included 191 FFS events with ADT + AAP
and 354 with ADT alone. An absolute improvement of 44%
in 3-yr FFS was observed in “low-risk” patients treated
with ADT + AAP (76% ADT + AAP vs 32% ADT; HR: 0.25, 95%
CI [0.17–0.33]; Fig. 2C). An absolute improvement of 33%
in 3-yr FFS was also observed in high-risk patients (45%
AAP vs 12% ADT; HR: 0.31, 95% CI [0.25–0.39]; Fig. 2D).
There was no evidence of heterogeneity for ADT + AAP
between the high- and low-risk subgroups (p-interac-
tion = 0.29; Fig. 3).
3.5. Additional efficacy endpoints
Additional efficacy measures evaluated the impact of
ADT + AAP on SREs, PFS, and PCSD within high- and low-
risk subgroups. In low risk, a 12% absolute improvement in
SRE-free survival at 3 yr favoured ADT + AAP treatment
(91%) compared with ADT alone (79%; HR: 0.31, 95% CI
[0.18–0.54]; Supplementary Fig. 1A). A further absolute
improvement of 25% in low-risk 3-yr PFS favoured ADT +
AAP (81%) compared with ADT alone (56%; HR: 0.33, 95% CI
[0.23–0.48]; Supplementary Fig. 2A). Furthermore, a 7%
absolute reduction in PCSD at 3 yr favoured ADT + AAP (89%)
compared with ADT alone (82%). The competing-risk
subhazard ratio for PCSD in the low-risk subgroup was
0.51 (95% CI [0.31–0.84]). Similar results were found across
all these three additional endpoints in the high-risk
subgroup (Supplementary Fig. 1–3). There was no evidence
of heterogeneity in benefit afforded by the ADT + AAP
combination between low- and high-risk subgroups for
SREs, PFS, and PCSD (Fig. 3).
3.6. CHAARTED “volume” stratification
An exploratory analysis was undertaken stratifying patients
by disease volume on bone scan according to the CHAARTED
Fig. 2 – Kaplan-Meier curves according to M1 risk stratification using the LATITUDE criteria for overall survival (OS)—(A) low risk and (B) high risk, and
failure-free survival (FFS)—(C) low risk and (D) high risk. AAP = abiraterone acetate and prednisolone; ADT = androgen deprivation therapy.
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Fig. 3 – Forest plot of hazard ratios (HRs) for AAP from adjusted Cox models on overall survival, failure-free survival, skeletal-related events,
progression-free survival, and prostate cancer–specific death within LATITUDE low- and high-risk subgroups. AAP = abiraterone acetate and
prednisolone; ADT = androgen deprivation therapy; CI = confidence interval.
Fig. 4 – Forest plot of hazard ratios (HRs) for AAP from adjusted Cox models on overall survival, failure-free survival, skeletal-related events,
progression-free survival, and prostate cancer–specific death within CHAARTED low and high-volume subgroups. AAP = abiraterone acetate and
prednisolone; ADT = androgen deprivation therapy; CI = confidence interval.
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trial criteria (Fig. 4). ADT + AAP conferred a significant
improvement in survival of 6% (83% vs 77%) at 3 yr
compared with ADT alone in low-volume disease (HR:
0.64, 95% CI [0.42–0.97]; Fig. 5). A 42% absolute gain was
also seen in 3-yr FFS with ADT + AAP (74%) compared with
ADT (32%) in low-volume disease (HR: 0.26, 95% CI [0.19–
0.36]; Fig. 5). No evidence of heterogeneity of effect by
ADT + AAP was observed for OS (p-interaction = 0.77) or FFS
(p-interaction = 0.47). ADT + AAP treatment advantages
were consistent throughout all additional efficacy end-
points irrespective of volume subgroup stratification
(Fig. 4).
3.7. Exploratory analysis in LATITUDE low risk and CHAARTED
low volume
LATITUDE and CHAARTED definitions differ, such that 18%
(n = 164/901) of patients identified as having a low risk/
volume according to one definition were stratified as having
a high risk/volume by the other (Fig. 1). We therefore
evaluated the efficacy of ADT + AAP in patients from lower-
risk/volume categories using both LATITUDE and CHAARTED
definitions. In the “double-low” subgroup of 333 patients,
ADT + AAP again demonstrated significant improvements
over ADT alone in OS (HR: 0.56, 95% CI [0.34–0.94]) and FFS
(HR: 0.21, 95% CI [0.14–0.30]; Supplementary Table 1, and
Supplementary Figs. 4 and 5).
3.8. Sensitivity analysis of patients with de novo metastatic
disease
The analysis of STAMPEDE patients by metastatic burden
may be influenced by patients with recurrent disease
following previous radical treatment. Exclusion of patients
receiving prior radical therapy provided a de novo cohort of
859 patients. The cohort was stratified according to the
LATITUDE risk criteria (Supplementary Fig. 6) and second-
arily by the CHAARTED volume criteria (Supplementary Fig.
7). Benefit of ADT + AAP over ADT alone was observed for all
subgroups, irrespective of risk or volume stratification
throughout all endpoints. The relative hazard for survival in
de novo low-risk patients was slightly superior to the
original cohort analysis (see section 3.3; HR: 0.64, 95% CI
[0.42–0.97]). A similar result was seen for low-volume
subgroup survival analysis (HR: 0.60, 95% CI [0.39–0.92]).
4. Discussion
The results from this STAMPEDE analysis support the use of
ADT + AAP in men with mHNPC irrespective of “risk” or
Fig. 5 – Kaplan-Meier curves according to M1 volume stratification using the CHAARTED criteria for overall survival (OS)—(A) low volume and (B) high
volume, and failure-free survival (FFS)—(C) low volume and (D) high volume. AAP = abiraterone acetate and prednisolone; ADT = androgen deprivation
therapy.
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“volume” stratifications. The ADT + AAP benefit extended
throughout all measured efficacy endpoints with a clear
survival advantage in the de novo metastatic setting (HR:
0.59, 95% CI [0.47–0.74]). The survival benefit with ADT +
AAP extends to the entire M1 cohort, irrespective of
subgroup classification as defined by the LATITUDE or
CHAARTED criteria, on each of the efficacy outcome
measures. There was no evidence of subgroup interaction
to support preferential subgroup ADT + AAP treatment
selection. However, four times the number of low-risk
patients required treatment to match the OS observed in
high-risk patients. The high-risk de novo group in
STAMPEDE showed a 48% relative reduction in the risk of
death and a 69% relative risk reduction in treatment failure,
complementing the conclusions from the LATITUDE trial
[1]. However, the outcome in low-risk M1 patients had not
been directly scrutinised, because such patients were not
recruited in LATITUDE, and “risk”/”volume” categorisation
was not applied prospectively in STAMPEDE. Image analysis
subsequent to the primary report of the STAMPEDE
“abiraterone comparison" demonstrates a 34% lower rela-
tive risk of death and a 76% lower relative risk of treatment
failure in the “low-risk” subgroup. The improvement in
outcome in this subgroup is comparable with that in the
“high-risk” patients evaluated in the LATITUDE trial, which
reported a 38% lower relative risk of death in the ADT + AAP
group compared with the ADT group, and a 53% lower
relative risk of radiological progression or death [1]. The
advantages of ADT + AAP treatment in low- and high-risk
disease extend throughout all exploratory outcome mea-
sures, including reductions in SREs, PFS, and PCSD. The
results also show that 37% of M1 patients are identified with
low-volume and low-risk mHNPC. This subgroup may
potentially benefit from ADT + AAP combination therapy,
yet are presently denied treatment based on the current
risk-based license indications for AAP [3,4].
There are inherent limitations to a post hoc subgroup
analysis of this type, including primarily the retrospective
nature of its design. Despite this, the proportion of patients
with evaluable scans was large, with the additional benefit
of comprehensive follow-up. The metastatic burden was
evaluated using conventional, as opposed to newer imaging
modalities, in concordance with previously defined volume
criteria. This radiological limitation was balanced by an
understanding that the true utility of novel imaging
modalities such as prostate-specific membrane antigen
positron emission tomography scanning remains to be
determined. Consequently, such imaging modalities are not
currently used widely in clinical decision making in
mHNPC. Interpretation of all conventional imaging is
subject to interobserver variation. We endeavoured to
minimise this by centralisation and reanalysis of all imaging
modalities independently of the main trial team. Objectivity
of results was maintained using a standardised approach to
radiological interpretation, blinding reviewers to the
outcome of treatment and using predefined subgroup
criteria for low risk/volume as defined by other groups.
Incorporation of an imaging quality control process within
the study design added confidence to this centralised
imaging reporting methodology. A further study limitation
is reflected in the patient cohort itself. The majority of
patients in our study had de novo M1 disease. Application of
our results to patients who develop M1 disease after prior
local therapy will require further evaluation.
Within current international practice, there is incom-
plete understanding and consensus for what constitutes an
optimal definition of “disease burden” [12]; current
definitions of risk stratification are cited [1,10,13–17]. Var-
iations in the prevalence of “low-burden” disease across
these definitions can vary between 23% and 44%, poten-
tially influencing volume-based treatment decisions
[18]. Current definitions also fail to acknowledge the poor
prognostic implication of combined bone and metastatic
nodal disease [19]. Emerging exploratory analysis within
oligometastatic HNPC patients treated with prostatic
radiotherapy suggests that nodal and/or fewer than four
bone metastases stratify patients with the greatest
accuracy [20]. Accepting these limitations, we incorporat-
ed subgroup radiological stratification according to LATI-
TUDE and CHAARTED trial definitions because of their
current clinical influence in guiding ADT + AAP and
docetaxel treatment in mHNPC. The consistency of ADT +
AAP benefit between the two stratified subgroup criteria
limits the bias associated with conclusions drawn from a
single stratified definition. Scrutinising the magnitude of
stratified subgroup discrepancy between the LATITUDE
and CHAARTED criteria revealed stratification mismatch in
18% of the trial cohort. Despite this, even when only
patients with low-risk and low-volume criteria using both
definitions were considered, there was significant evi-
dence of improved OS and FFS in patients treated with
ADT + AAP. International guidance should now be re-
evaluated to consider altering the licenced indications to
include the use of ADT + AAP in M1 patients irrespective of
radiological disease burden as an alternative to ADT +
docetaxel [21–23].
The treatment landscape for “low-burden” (oligometa-
static) mHNPC is undergoing rapid evolution following
presentation of these data and those presented in the
STAMPEDE M1 radiotherapy comparison [24]. The latter
demonstrated a 32% relative reduction in the risk of death
(HR: 0.68, 95% CI [0.52–0.90]) in oligometastatic patients.
Current speculation relating to the low-burden benefit of
docetaxel in this setting will be addressed following the
release of the STAMPEDE docetaxel long-term data analysis
in 2019. In future, the benefit of combining focal and
systemic therapy for low-burden mHNPC requires clarity,
and will be addressed by the PEACE 1 trial (NCT01957436)
and future STAMPEDE-based study. Metastasis-directed
therapy may also provide further disease control benefits as
recently demonstrated, but this requires clarification in
light of developments in adjuvant therapies and novel
imaging [25].
5. Conclusions
Men with mHNPC benefit from ADT + AAP irrespective of
whether they have LATITUDE low/high-risk or CHAARTED
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low/high-volume categorisation. The license indications for
the use of this combination treatment irrespective of “risk”
or “volume” classification should now be reconsidered.
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